Real-Time PCR, Digital PCR and End-Point PCR Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The real-time pcr, digital pcr and end-point pcr market size has grown strongly in recent years. It will grow from $38.37 billion in 2024 to $41.88 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to standardization of PCR protocols, role in personalized medicine, contribution to drug discovery and development, adoption in forensic and paternity testing.

The real-time pcr, digital pcr and end-point pcr market size is expected to see strong growth in the next few years. It will grow to $60.91 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to expansion of molecular diagnostics, growth in infectious disease testing, increasing demand for genetic testing, market penetration in research and forensics, rapid point-of-care PCR solutions. Major trends in the forecast period include emergence of digital assays, multiplex PCR advancements, shift towards digital PCR technology, automation and high-throughput systems, miniaturization of PCR platforms.

The anticipated rise in infectious diseases is set to drive the growth of the real-time PCR, digital PCR, and end-point PCR markets. Infectious diseases, caused by the proliferation of pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, can be effectively addressed using PCR technologies. Real-time PCR, digital PCR, and end-point PCR play crucial roles in quantifying specific pathogens or their genetic material, monitoring disease progression, and swiftly diagnosing infections such as HIV, hepatitis, respiratory viruses, and tuberculosis. For instance, UNAIDS reported a global increase in the population living with HIV to 39 million in 2022, representing a 3.17% rise from 37.7 million in 2020, with approximately 1.3 million new HIV infections reported in 2022. Moreover, in the United States, the Centers for Disease Control and Prevention noted a rise in tuberculosis cases to 8,300 in 2022 from 7,874 in 2021. Thus, the escalating incidence of infectious diseases is a driving force behind the growth of the PCR markets.

The growth of chronic diseases is poised to propel the real-time PCR, digital PCR, and end-point PCR markets. Chronic diseases, persistent over an extended period and often worsening over time, are a significant focus for PCR applications. Real-time PCR aids in the early and accurate diagnosis of chronic conditions by detecting specific DNA or RNA markers associated with diseases such as cancer, diabetes, and viral infections. The World Health Organization reported 41 million deaths globally annually, with 74% attributed to non-communicable diseases, including 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Consequently, the increasing prevalence of chronic diseases is a key driver for the real-time PCR, digital PCR, and end-point PCR markets.

Key players in the real-time PCR, digital PCR, and end-point PCR markets are actively pursuing the development of innovative products, leveraging advanced technologies such as digital polymerase chain reaction (dPCR). This cutting-edge biotechnological refinement of conventional PCR methods enables the direct quantification and clonal amplification of nucleic acid strands, encompassing DNA, cDNA, or RNA. Notably, major companies are at the forefront of adopting dPCR technology to gain a deeper understanding of patients' conditions, whether related to cancer, genetic diseases, or infections. An illustrative example is Roche Diagnostics, a prominent US-based manufacturer of medicines and medical devices, which unveiled the next-generation Digital LightCycler System in August 2022. Specifically designed for the early detection and treatment of various chronic and genetic disorders, this advanced system introduces automation to workflow and data management. It eliminates the need for external calculations, software, and processors. Boasting three nano well plate configurations, six advanced optical channels, and 5x concentrated DNA and RNA master mixes, the Digital LightCycler System ensures high sensitivity and precision. This addition enhances Roche's diagnostic platforms, offering advanced technology, clinical applications, customization and flexibility, along with streamlined workflow automation.

In April 2024, Bio-Rad Laboratories Inc., a US-based research company known for its real-time PCR and digital PCR technologies, formed a partnership with Oncocyte Corporation. The collaboration is focused on developing and commercializing advanced transplant monitoring products utilizing Droplet Digital PCR technology. This partnership aims to improve non-invasive organ health assessments by sensitively analyzing cell-free DNA biomarkers, ultimately enhancing patient outcomes in transplant care. Oncocyte Corporation is a US-based biotechnology research company specializing in precision diagnostics for cancer and transplant monitoring.

Major companies operating in the real-time PCR, digital PCR and end-point PCR market report are F. Hoffmann La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Co., GE HealthCare Technologies Inc., Agilent Technologies Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., QIAGEN N.V., Eppendorf Group, Promega Corporation, Meridian Bioscience Inc., Takara Bio Inc., Cole-Parmer Instrument Company LLC, Bioneer Corporation, Enzo Life Sciences Inc., Analytik Jena AG, Fluidigm Corporation, Elitech Group SAS, Microsynth AG, Stilla Technologies SAS, HTG Molecular Diagnostics Inc., AITbiotech Pte Ltd., Bio Molecular Systems, JN Medsys Pte Ltd., Biomeme Inc.

North America was the largest region in the real-time PCR, digital PCR, and end-point PCR market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the real-time pcr, digital pcr and end-point pcr market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the real-time pcr, digital pcr and end-point pcr market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The real-time PCR, digital PCR, and end-point PCR market include revenues earned by entities by providing services such as quantitative analysis, real-time monitoring, high sensitivity and specificity, gene expression analysis, absolute quantification, rare event detection, qualitative detection, and molecular cloning. The market value includes the value of related goods sold by the service provider or included within the service offering. The real-time PCR, digital PCR, and end-point PCR market also include sales of thermal cyclers, fluorescent probes, quantitative data output, standard curves, real-time PCR reagents, partitioning chips or plates, digital PCR instruments, and PCR master mixes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Real-time PCR (polymerase chain reaction), digital PCR, and endpoint PCR are distinct techniques in molecular biology and genetic analysis employed for amplifying and analyzing DNA samples. Real-time PCR is a laboratory technique used to amplify and quantify DNA or RNA molecules. Digital PCR is the third generation of PCR that enables precise quantification by segregating a sample into numerous isolated compartments. Endpoint PCR, also known as conventional PCR, is a fundamental molecular biology technique used to amplify a specific DNA sequence from a sample. These PCR techniques are utilized in various clinical applications, including bacteria detection, DNA fingerprinting, and genetic disorder diagnosis.

The main products associated with real-time PCR, digital PCR, and endpoint PCR include instruments, consumables and reagents, software, and services. Instruments refer to devices, tools, or equipment designed for measurement, analysis, manipulation, or control of physical, chemical, or biological phenomena. Various technologies, such as quantitative, endpoint PCR, and digital PCR, are used for clinical, research, forensic, and other applications, with different end-users including hospitals, diagnostic labs, pharmaceutical and biotechnology companies, and contract research organizations.

The real-time PCR, digital PCR and end-point PCR market research report is one of a series of new reports that provides real-time PCR, digital PCR and end-point PCR market statistics, including real-time PCR, digital PCR and end-point PCR industry global market size, regional shares, competitors with a real-time PCR, digital PCR and end-point PCR market share, detailed real-time PCR, digital PCR and end-point PCR market segments, market trends and opportunities, and any further data you may need to thrive in the real-time PCR, digital PCR and end-point PCR industry. This real-time PCR, digital PCR and end-point PCR market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.